NCT02183168View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

July 1, 2001

Primary Completion Date

May 1, 2002

Conditions
Spondylitis, Ankylosing
Interventions
DRUG

Meloxicam suppository

DRUG

Meloxicam tablet

DRUG

Indomethacin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02183168 - Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter